2017
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Abstract: INTRODUCTION CSF analysis and other measurements of amyloidosis, such as amyloid-binding positron emission tomography (PET) studies, are limited by cost and availability. There is a need for a more practical Aβ biomarker for central nervous system (CNS) amyloid deposition. METHODS We adapted our previously reported Stable Isotope Labeling Kinetics (SILK) protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. RESULTS Aβ isoforms have a half-life of approximatel…
Search citation statements
Paper Sections
Select...
430
113
101
23
Citation Types
42
565
6
9
Year Published
1970
2026
Publication Types
Select...
473
73
42
18
Relationship
34
572
Authors
Journals
Cited by 572 publications
(622 citation statements)
References 19 publications
42
565
6
9
“…Taken together, the observations from this study suggest that pre-enrichment of Aβ peptides from blood plasma by immunoprecipitation with an antibody against the Aβ N-terminus and in the presence of detergents can substantially facilitate the measurement of specific Aβ variants by a commercially available multiplex immunoassay. Furthermore, our findings support the results of two recent IP-MS studies reporting highly accurate prediction of cerebral amyloid pathology by the blood plasma ratios Aβ42/Aβ40 [ 6 ] and Aβ1–40/Aβ1–42 [ 7 ]. Major limitations of our current study include the small sample size, the need for assay standardization and automatization of manual steps, and the need for inclusion of reference material for normalization between assay plates and experiments.…”
Section: Resultssupporting
confidence: 90%
“…Taken together, the observations from this study suggest that pre-enrichment of Aβ peptides from blood plasma by immunoprecipitation with an antibody against the Aβ N-terminus and in the presence of detergents can substantially facilitate the measurement of specific Aβ variants by a commercially available multiplex immunoassay. Furthermore, our findings support the results of two recent IP-MS studies reporting highly accurate prediction of cerebral amyloid pathology by the blood plasma ratios Aβ42/Aβ40 [ 6 ] and Aβ1–40/Aβ1–42 [ 7 ]. Major limitations of our current study include the small sample size, the need for assay standardization and automatization of manual steps, and the need for inclusion of reference material for normalization between assay plates and experiments.…”
Section: Resultssupporting
confidence: 90%
“…Our findings are in agreement with some previous reports suggesting that a low Aβ42/Aβ40 ratio and/or a low Aβ42 level in plasma represent candidate biomarkers of neuropathological changes related to AD [ 6 , 11 , 24 , 26 – 29 ]. However, this is not supported by several other studies [ 25 , 30 – 32 ].…”
Section: Discussionsupporting
confidence: 93%
“…We found that the median and mean AβX–42/X–40 plasma ratios (measured with mAb 6E10) were decreased by 15–16% in amyloid-positive study participants relative to amyloid-negative subjects. This figure is in reasonable agreement with published observations [ 1 , 2 , 15 ]. The differences in the corresponding median and mean Aβ1–42/1–40 plasma ratios (measured with mAb 3D6) between the amyloid pathology subgroups were 20.86% and 18.34%, respectively, indicating an accentuation of contrast.…”
Section: Discussionsupporting
confidence: 94%
“…Average concentrations of plasma Aβ were 329.5 pg/mL for Aβ40 and 48.0 pg/mL for Aβ42 for these 36 individuals, with a standard deviation of 89.4 and 12.8 pg/mL, respectively. The average concentrations of plasma Aβ from this study were similar to what has been reported previously . Furthermore, all individual concentrations were within the linear ranges for our developed assay (Figure b,c).…”
Section: Resultssupporting
confidence: 88%
